Catechol-O-methyltransferase (COMT) pharmacogenetics in the treatment response phenotypes of major depressive disorder (MDD)

CNS and Neurological Disorders - Drug Targets

Volumn 11, Issue 3, 2012, Pages 264-272

  Kocabas, Neslihan Aygun ^a,b  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b GAZI UNIVERSITY   (Turkey)

Author keywords

Antidepressant; COMT gene; Pharmacogenetics; snp; Treatment response

Indexed keywords

ANTIDEPRESSANT AGENT; CATECHOL METHYLTRANSFERASE; CITALOPRAM; DOPAMINE; DULOXETINE; FLUOXETINE; FLUVOXAMINE; MILNACIPRAN; MIRTAZAPINE; PAROXETINE; SEROTONIN;

ALLELE; ARTICLE; COGNITION; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME STRUCTURE; EXON; GENE EXPRESSION; GENE FREQUENCY; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENOTYPE ENVIRONMENT INTERACTION; HAMILTON SCALE; HAPLOTYPE; HUMAN; MAJOR DEPRESSION; NONHUMAN; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; PREFRONTAL CORTEX; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 84861719385     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152712800672445     Document Type: Article

References (86)

1. Weinshilboum, R.M.; Wang, L. Pharmacogenomics: Bench to Bedside. Nat. Rev. Drug Discov., 2004, 3, 739-748.
2. Wang, L.; Weinshilboum, R.M. Pharmacogenomics: candidate gene identification, functional validation and mechanisms. Hum. Mol. Genetics, 2008, 17, 174-179.
3. Drago, A.; De Ronchi, D.; Serretti, A. Pharmacogenetics of antidepressant response: an update. Hum. Genomics, 2009, 3, 257-274.
4. Palmer, L.; Cardon, L. Shaking the tree: mapping complex disease genes with linkage disequilibrium. Lancet, 2006, 366, 1223-1234.
5. Leckband, S.G.; Bishop, J.R.; Ellingrod, V.L. Pharmacogenomics in Psychiatry. J. Pharm. Practice, 2011, inpress.
6. Schosser, A.; Calati, R.; Serretti, A.; Massat, I.; Kocabas, N.A.; Papageorgiou, K.; Linnotte, S.; Mendlewicz, J.; Souery, D.; Zohar, J.; Juven-Wetzler, A.; Montgomery, S.; Kasper, S. The impact of COMT gene polymorphisms on suicidality in treatment resistant major depressive disorder: An European Multicenter Study. Eur. Neuropharmacol., 2012, 22(4), 259-266.
7. Mulder, R.T.; Joyce, P.R.; Frampton, C.M.A.; Luty, S.E.; Sullivan, P.F. Six months of treatment for depression: outcome and predictors of course of illness. Am. J. Psychiatry, 2006, 166, 95-100.
8. Murray, C.J.; Lopez, A.D. Evidence-based health policy-lessons from the Global Burden of disease study. Science, 2006, 274, 740-743.
9. Asberg, M.; Martensson, B. Serotonin Selective antidepressant drugs: past, current, future. Clin. Neuropharmacol., 1993,16, 32-44.
10. Crisafulli, C.; Fabbri, C.; Porcelli, S.; Drago, A.; Spina, E.; Ronchi, D.; Serretti, A. Pharmacogenetics of antidepressants. Front. Pharmacol., 2011, 2, 1-14.
11. Millan, M.J. Multi target strategies for the improved treatment of depressive stages; conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol. Ther., 2006, 110, 135-370.
12. Kemp, A.H.; Gordon, E.; Rush, A.J.; Williams, L.M. Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging and genetic measures. CNS Spectr., 2008, 13, 1066-1086.
13. Reynolds, G.P. The impact of pharmacogenetics on the development and use of antipsychotic drugs. Drug Discov. Today, 2007, 12, 953-959.
14. Souery, D.; Oswald, P.; Massat, I.; Bailer, U.; Bollen, J.; Demyttenaere, K. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J. Clin. Psychiatry, 2007, 68, 1062-1070.
15. Ruhé, H.G.; van Rooijen, G.; Spijker, J.; Peeters, F.P.; Schene, A.H. Staging methods for treatment resistant depression. A systematic review. J. Affect. Disorder., 2012, 137(1-3), 35-45.
16. Gudayol-Ferré, E.; Herrera-Guzmán, I.; Camarena, B.; Cortés-Penagos, C.; Herrera-Abarca, J.E.; Martínez-Medina, P.; Cruz, D.; Hernández, S.; Genis, A.; Carrillo-Guerrero, M.Y.; Avilés Reyes, R.; Guàrdia-Olmos, J. The role of clinical variables, neurophysiological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in MDD. J. Affect. Disorder., 2010,127, 343-351.
17. Papakostas, G.I.; Perlis, R.H.; Scalia, M.J.; Petersen, T.J.; Fava, M. A meta analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J. Clin. Psychopharmacol., 2006, 26, 56-60.
18. Posternak, M.A.; Zimmerman, M. Is there a delay in antidepressant effect? A meta analysis. J. Clin. Psychiatry, 2005, 66, 148-158.
19. Kato, M.; Serretti, A. Review and meta-analysis of antidepressant pharmacogenetics findings in major depressive disorder. Mol. Psychiatry, 2010, 15, 473-500.
20. Horstmann, S.; Binder, E. Pharmacogenomics of antidepressant drugs. Pharmacol. Ther., 2009, 124, 57-73.
21. O'Reilly, R.L.; Bogue, L.; Singh, S.M. Pharmacogenetic response to antidepressants in a multicase family with affective disorder. Biol. Psychiatry, 1994, 36, 467-471.
22. Lerer, B.; Macciardi, F. Pharmacogenetics of antidepressants and mood-stabilizing drugs: a review of candidate -gene studies and future research directions. Int. J. Neuropsychopharmacol., 2002, 5, 255-275.
23. Schosser, A.; Kasper, S. The role of Pharmacogenetics in the treatment of depression and anxiety disorders. Int. Clin. Psychopharmacol., 2009, 24, 277-288.
24. Serretti, A.; Artioli, P.; Quartesan, R. Pharmacogenetics in the treatment of depression: pharmacodynamic studies. Pharmacogenet. Genomics, 2005, 15, 61-67.
25. Manolio, T.A.; Collins, F.S.; Cox, N.J.; Goldstein, D.B.; Hindorff, L.A.; Hunter, D.J.; McCarthy, M.I.; Ramos, E.M.; Cardon, L.R.; Chakravarti, A.; Cho, J.H.; Guttmacher, A.E.; Kong, A.; Kruglyak, L.; Mardis, E.; Rotimi, C.N.; Slatkin, M.; Valle, D.; Whittemore, A.S.; Boehnke, M.; Clark, A.G.; Eichler, E.E.; Gibson, G.; Haines, J.L.; Mackay, T.F.; McCarroll, S.A.; Visscher, P.M. Finding the missing heritability of complex diseases. Nature, 2009, 461, 747-753.
26. Mitchell, K.J.; Porteous, D.J. GWAS for psychiatric disease: is the framework built on a solid foundation? Mol. Psychiatry, 2009, 8, 740-741.
27. McMahon, F.J.; Buervenich, S.; Charney, D.; Lipsky, R.; Rush, A.J.; Wilson, A.F. Variation in the gene encoding the Serotonin 2A receptor is associated with outcome of ADT. Am. J. Hum. Genet., 2006, 78, 804-814.
28. Garriock, H.A.; Kraft, J.B.; Shyn, S.I.; Peters, E.J.; Yokoyoma, J.S.; Jenkins, G.D. A genome wide association study of citalopram response in major depressive disorder. Biol. Psychiatry, 2010, 67,133-138.
29. Ising, M.; Lucae, S.; Binder, EB.; Bettecken, T.; Uhr, M.; Ripke, S.; Kohli, M.A.; Hennings, J.M.; Horstmann, S.; Kloiber, S.; Menke, A.; Bondy, B.; Rupprecht, R.; Domschke, K. A genome wide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch. Gen. Psychiatry, 2009, 66, 966-975.
30. Uher, R.; Perroud, N.; Ng, M.Y.; Hauser, J.; Henigsberg, N.; Maier, W.; Mors, O.; Placentino, A.; Rietschel, M.; Soury, D.; Zagar, T.; Czerski, P.M.; Jerman, B.; Larsen, E.R.; Schulze, T.G.; Zobel, A.; Cohen- Woods, S.; Pirlo, K.; Butler, A.W.; Muglia, P.; Barnes, M.R.; Lathrop, M.; Farmer, A.; Breen, G.; Aitchison, K.J.; Craig, I.; Lewis, C.M.; McGuffin, P. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am. J. Psychiatry, 2010, 167, 555-564.
31. Shi, J.; Potash, J.B.; Knowles, J.A.; Weissman, M.M.; Coryell, W.; Scheftner, W.A.; Lawson, W.B.; DePaulo, J.R.; Gejman, P.V.; Sanders, A.R.; Johnson, J.K.; ADTams, P.; Chaudhury, S.; Jancic, D.; Evgrafov, O.; Zvinyatskovskiy, A.; Ertman, N.; Giadis, M.; Neimanas, K.; Goodell, M.; Hale, N.; Ney, N.; Verma, R.; Mirel, D.; Holmans, P.; Levinson, D.F. Genome-wide association study of recurrent early-onset major depressive disorder. Mol. Psychiatry, 2011, 16, 193-201.
32. Shyn, S.I.; Shi, J.; Kraft, J.B.; Potash, J.B.; Knowles, J.A.; Weissman, M.M.; Garriock, H.A.; Yokoyama, J.S.; McGrath, P.J.; Peters, E.J.; Scheftner, W.A.; Coryell, W.; Lawson, W.B.; Jancic, D.; Gejman, P.V.; Sanders, A.R.; Holmans, P.; Slager, S.L.; Levinson, D.F.; Hamilton, S.P. Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies. Mol. Psychiatry, 2011, 16, 202-215.
33. Hosak L. Role of COMT gene Val158Met polymorphism in mental disorders: A review. Eur. Psychiatry, 2007, 22, 276-281.
34. Mannisto P.T.; Kaakkola, S. Catechol-O-methyltransferase (COMT) biochemistry, Molecular biology, Pharmacology, and Clinical Efficacy of the new selective COMT inhibitors. Pharmacol. Rev., 1999, 51, 593-628.
35. Michaelovsky, E.; Gothelf, D.; Korostishevsky, M.; Frisch, A.; Burg, M.; Carmel, M.; Association between a common haplotype in the COMT gene region and psychiatric disorders in individuals with 22q11.2DS. Int. J. Neuropsychopharmacol., 2007, 11, 351-363.
36. Funke, B.; Malhotra, A.K.; Finn, C.T.; Plocik, A.M.; Lake, S.L.; Lencz, T.; DeRosse, P.; Kane, J.M.; Kucherlapati, R. COMT genetic variation confers risk for psychotic and affective disorders: a case control study. Behav. Brain Funct., 2005, 1, 9-28.
37. Mier, D.; Kirsch, P.; Meyer-Lindenberg, A.M. Neural substrates of pleiotropic action of genetic variation in COMT: a meta-analysis. Mol. Psychiatry, 2009, 1-10.
38. Lachman, H.M.; Papolos, D.F.; Saito, T.; Yu, Y.M.; Szumlanski, C.L.; Weinshilboum, R.M. Human Catechol O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics, 1996, 6, 243-250.
39. Shield, A.J.; Thomae, B.A.; Eckloff, B.W., Wieben, E.D.; Weinshilboum, R.M. Human catechol O-methyltransferase genetic variation: gene resequencing and functional characterization of variant allozymes. Mol. Psychiatry, 2004, 9, 151-160.
40. Tenhunen, J.; Salminen, M.; Lundstrom, K.; Kiviluoto, T.; Savolainen, M.; Ulmanen, I. Genomic organisation of the human Catechol O-methyltransferase (COMT) gene and its expression from two distinct promoters. Eur. J. Biochem., 1994, 223, 1049-1059.
41. Männistö, P.T.; Kaakkola, S. Catechol O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of new selective COMT inhibitors. Pharmacol. Rev., 1999, 51, 593-628.
42. Karoum, F., Chrapusta, S.; Egan, M.F. 3-methoxytryptamine is the major metabolite of released dopamine in the rat frontal cortex: reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in the frontal cortex, nucleus accumbens and striatum by a simple two pool model. J. Neurochem., 1994, 63, 972-979.
43. Diaz-Asper, C.M.; Weinberger, D.R.; Goldberg, T.E. Catechol O-methyltransferase polymorphisms and some implications for cognitive therapeutics. Neurotherapeutics, 2006, 3, 97-105.
44. Gogos, J.A.; Morgan, M.; Luine, V.; Santha, M.; Ogawa, S.; Pfaff, D.; Karayiorgou, M.; Catechol O-methyltransferase deficit mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc. Nat. Acad. Sci., 1998, 95, 9991-9996.
45. Huotari, M.; Gogos, J.A.; Karayiorgou, M.; Koponene, O.; Forsberg, M.; Raasmaja, A. et al. Brain catecholamine metabolism in Catechol O-methyltransferase deficit mice. Eur. J. Neurosci., 2002, 15, 246-256.
46. Shifman, S.; Bronstein, M.; Sternfeld, M.; Pisanté-Shalom, A.; Lev-Lehman, E.; Weizman, A.; Reznik, I.; Spivak, B.; Grisaru, N.; Karp, L.; Schiffer, R.; Kotler, M.; Strous, R.D.; Swartz-Vanetik, M.; Knobler, H.Y.; Shinar, E.; Beckmann, J.S.; Yakir, B.; Risch, N.; Zak, N.B.; Darvasi, A. A highly significant association between COMT haplotype and schizophrenia. Am. J. Hum. Genet., 2002, 71, 1296-1302.
47. Bialecka, M.; Kurzawski, M.; Klodowska-Duda, G.; Opala, G.; Tan, E.K.; Drozdzik, M. The association of functional Catechol O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications. Pharmacogenet. Genomics, 2008, 18, 815-821.
48. Gupta, M.; Bhatnagar, P.; Grover, S.; Kaur, H.; Bagel, R.; Bhasin, Y.; Chauhan, C.; Verma, B.; Manduva, V.; Mukherjee, O.; Purushottam, M.; Shara, A.; Jain, S.; Brahmachari, S.K.; Kukreti, R. Association studies of Catechol O-methyltransferase gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics, 2009, 10, 385-397.
49. Nackley, A.G.; Shabalina, S.A.; Tchivileva, I.E.; Sattarfield, K.; Korchynskyi, O.; Makarov, S.S., Maixner, W.; Diatchenko, L. Human Catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science, 2006, 314, 1930-1932.
50. Weinshilboum, R.M.; Otterness, D.M.; Szumlanski, C.L. Methylation pharmacogenetics: Catechol O-methyltransferase, thiopurine methyltransferase and histamine N-methyltransferase. Annu. Rev. Pharmacol. Toxicol., 1999, 39, 19-52.
51. Chen, J.; Lipska, B.K.; Halim, N.; Ma, Q.D.; Matsumoto, M.; Melhem, S.; Kolachana, B.S.; Hyde, T.M.; Herman, M.M.; Apud, J.; Egan, M.F.; Kleinman, J.E.; Weinberger, D.R. Functional analysis of genetic variation in Catechol-O-methyltransferase (COMT): Effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Genet., 2004, 75, 807-821.
52. Harrison, P.J.; Tunbridge, E.M. Catechol O-methyltransferase: A gene contributing to sex differences in brain function, and to sexual dimorphism in the predisposition to psychiatric disorders. Neuropsychopharmacology, 2008, 33, 3037-3045.
53. Palmatier, M.A.; Kang, A.M.; Kidd, K.K. Global variation in the frequencies of functionally different COMT alleles. Biol. Psychiatry, 1999, 46, 557-567.
54. Kocabas, N.A.; Karakaya, A.E.; Cholerton, S.; Sardas, S. Catechol O- methyltransferase (COMT) genetic polymorphisms in a Turkish population. Arch. Toxicol., 2001, 75, 407-409.
55. Jiang, H.; Xie, T.; Ramsden, D.B.; Ho, S.L. Human Catechol O- methyltransferase downregulation by estradiol. Neuropharmacology, 2003, 45, 1011-1018.
56. Shen, L.X.; Basilion, J.P.; Stanton, V.P. Single-nucleotide polymorphisms can cause different structural folds of mRNA. Proc. Natl. Acad. Sci., 1999, 96, 7871-7876.
57. Diatchenko, L.; Slade, G.D.; Nackley, A.G.; Bhalang, K.; Sigurdsson, A.; Belfer, I.; Goldman, D.; Xu, K.; Shabalina, S.A.; Shagin, D.; Max, M.B.; Makarov, S.S.; Maixner, W. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum. Molec. Genet., 2005,14, 135-143.
58. Nackley, A.G.; Shabalina, S.A.; Lambert, J.E.; Conrad, M.S.; Gison, D.G.; Sattarfield, K.; Diatchenko, L. Low enzymatic haplotypes of the human Catechol-O-methyltransferase gene: enrichment for marker SNPs. Plus One, 2009, 4, e5237.
59. DeMille, M.M.C.; Kidd, J.R.; Ruggeri, V.; Palmatier, M.A.; Goldman, D.; Odunsi, A.; Okonofua, F.; Grigorenko, E.; Schultz, L.O.; Bonne- Tamir, B.; Lu, R.B.; Parnas, J.; Pakstis, J.; Kidd, K.K. Population variation in linkage disequilibrium across the COMT gene considering promoter region and coding region variation. Hum. Genet., 2002, 111, 521-537.
60. Mukherjee, N.; Kidd, K.K.; Pakstis, A.J.; Speed, W.C.; Li, H.; Tarnok, Z. The complex global pattern of genetic variation and linkage disequilibrium at catechol-O-methyltransferase. Mol. Psychiatry, 2008, 1-10.
61. http=//www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?chooseRs=het&locusId=1312.
62. Porcelli, S.; Drago, A.; Fabbri, C.; Gibiino, S.; Callati, R.; Serretti, A. Pharmacogenetics of antidepressant response. J. Psychiatry Neurosci., 2011, 36, 87-113.
63. Lambert, G.; Johansson, M.; Agren, H.; Friberg, P. Reduced brain Norepinephrine and Dopamine release in treatment refractory depressive illness. Arch. Gen. Psychiatry, 2000, 57, 787-793.
64. Arias, B.; Serretti, A.; Lorenzi, C.; Gasto, C.; Catalan, R.; Fananas, L. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRI in depressive patients of European origin. J. Affec. Disord., 2006, 90, 251-256.
65. Illi, A.; Setala-Soikkeli,E.; Kampman, O.; Viikki, M.; Nuolivirta, T.; Poutanene, O.; Huhtala, H.; Mononen, N.; Lehtimaki, T.; Leinonen, E. Catechol O-methyltransferase Val108/158Met genotype, major depressive disorder and response to SSRI medication in major depressive disorder. Psychiatry Res., 2010, 176, 85-87.
66. Benedetti, F.; Colombo, C.; Pirovano, A.; Marino, E.; Smeraldi, E. The Catechol O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting. Psychopharmacology, 2009, 203, 155-160.
67. Smolders, I.; Clinckers, R.; Meurs, A.; De Bundel, D.; Portelli, J.; Ebinger, G.; Michotte, Y. Direct enhancement of hippocampal dopamine or serotonin levels as a pharmacodynamic measure of combined antidepressant-anticonvulsant action. Neuropharmacology, 2008, 54, 1017-1028.
68. Kobayashi, T.; Hayashi, E.; Shimamura, M.; Kinoshita, M.; Murphy, N.P. Neurochemical responses to antidepressants in the prefrontal cortex of mice and their efficacy in preclinical models of anxiety-like and depression-like behavior: a comparative and correlational study. Psychopharmacology, 2008, 197, 567-580.
69. Zangen, A.; Nakash, R.; Overstreet, D.H.; Yadid, G. Association between depressive behavior and absence of serotonin-dopamine interaction in the nucleus accumbens. Psychopharmacology, 2001,155, 434-439.
70. Dremencov, E.; Gispan-Herman, I.; Rosenstein, M.; Mendelman, A.; Overstreet, D.H.; Zohar, J.; Yadid, G. The serotonin-dopamine interaction is critical for fast-onset action of antidepressant treatment: in vivo studies in an animal model of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2004, 28, 141-147.
71. Baune, B.; Hohoff, C.; Berger, K.; Neumann, A.; Mortensen, S.; Roehrs, T.; Deckert, J.; Arolt, V.; Domschke, K. Association of the COMT val158met variant with AD response in major depression. Neuropsychopharmacology, 2008, 33, 924-932.
72. Szegedi, A.; Rujescu, D.; Tadic, A.; Muller, M.J.; Kohnen, R.; Stassen, H.H.; Dahman, N. Catechol O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J., 2005, 5, 49-53.
73. Kunugi, H.; Vallada, H.P.; Hoda, F.; Kirov, G.; Gill, M.; Aitchison, K.J.; Ball, D.; Arranz, M.J.; Murray, R.M.; Collier, D.A. No evidence for an association of affective disorders with highor low activity allele of Catechol O-methyltransferase gene. Biol. Psychiatry, 1997, 42, 282-285.
74. Ohara, K.; Nagai, M.; Suzuki Y. Low activity allele of Catechol O- methyltransferase gene and Japanese unipolar depression. Neuroreport, 1998, 9, 1305-1308.
75. Massat, I.; Souery, D.; Del-Favero, J.; Nothen, M.; Blackwood, D.; Muir, W.; Kaneva, R.; Serretti, A.; Lorenzi, C.; Rietschel, M.; Milanova, V.; Papadimitriou, G.N.; Dikeos, D.; Van Broekhoven, C.; Mendlewicz, J. Association between COMT (Val158Met) functional polymorphism and early onset in patients with major depressive disorder in a European multicenter genetic association study. Mol. Psychiatry, 2005, 10, 598-605.
76. Massat, I.; Kocabas, N.A.; Crisafulli, C.; Chiesa, A.; Calati, R.; Linotte, S.; Kasper, S.; Fink, M.; Antonijevic, I.; Forray, C.; Snyder, L.; Bollen, J.; Zohar, J.; De Ronchi, D.; Souery, D.; Serretti, A.; Mendlewicz, J. COMT and age at onset in mood disorders: a replication and extension study. Neurosci. Lett., 2011, 12, 498, 218-221.
77. Kocabas, N.A.; Faghel, C.; Barreto, M.; Kasper, S.; Mendlewicz, J.; Noro, M.; Souery, D.; Zohar, J.; Massat, I. The impact of Catechol O- methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study. Int. Clin. Psychopharmacol., 2010, 25, 218-227.
78. Yoshida, K.; Higuchi, H.; Takahashi, H.; Kamata, M.; Sato, K.; Inoue, K.; Itoh, K.; Ozaki, N. Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran. Hum. Psychopharmacol., 2008, 23, 121-128.
79. Spronk, D.; Arns, M.; Barnett, K.J.; Cooper, N.J.; Gordon, E. An investigation of EEG, genetic and cognitive markers of treatment response to antidepressant medication in patients with major depressive disorder: a pilot study. Affect. Disord., 2011, 128, 41-48.
80. Benedetti, F.; Dallapezia, S.; Colombo, C.; Lorenzi, C.; Pirovano, A.; Smeraldi, E. Effect of Catechol O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine. Eur. Psychiatry, 2010, 25, 476-478.
81. Tsai, S.J.; Gau, Y.T.A.; Hong, C.J.; Liou, Y.J.; Yu, Y.W.Y.; Chen, T.J. Sexually dimorphic effect of Catechol O-methyltransferase (COMT) val158met polymorphism on clinical response to fluoxetine in major depressive patients. J. Affect. Disord., 2009, 113, 183-187.
82. Perlis, R.H.; Fijal, B.; Adams, D.H.; Sutton, V.K.; Trivedi, M.H.; Houston, J.P. Variation in Catechol O-methyltransferase (COMT) is associated with duloxetine response in a clinical trial for major depressive disorder. Biol. Psychiatry, 2009, 65, 785-791.
83. Gabriel, S.B.; Shabalina, S.A.; Tchivileva, I.E.; Satterfield, K.; Korchynskyi, O.; Makarov, S.S.; Maixner, W.; Diatchenko, L. The structure of haplotype blocks in the human genome. Science, 2002, 296, 2225-2229.
84. Meyer-Lindenberg, A.; Nichols, T.; Callicott, J.H.; Ding, J.; Kolachana, B.; Buckholtz, J.; Mattay, V.S.; Egan, M.; Weinberger, D.R. Impact of complex genetic variation in COMT on human brain function. Mol. Psychiatry, 2006, 11, 867-877.
85. The Psychiatric GWAS Consortium Steering Committee. A framework for interpreting genome-wide association studies of psychiatric disorders. Mol. Psychiatry, 2009, 14, 10-17.
86. Uher, R. Genes, environment, and individual differences in responding to treatment for depression. Har. Rev. Psychiatry, 2011, 19, 109-124.